



Primary IR Contact

Investor Relations and Public Affairs

Phone: 650-837-8194

Fax: 650-837-8205

E-mail: shubbard@exelixis.com

Corporate Profile

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four approved products, CABOMETRYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO™ (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.

Recent Headlines

02/12/19

[Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update](#)

02/12/19

[Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts](#)

02/07/19

[Exelixis to Present at the Guggenheim Healthcare Talks Idea Forum / Oncology Day 2019 on February 14, 2019](#)

Upcoming Events

There are currently no events scheduled.

Stock Performance

EXEL (Common Stock)

Exchange NASDAQ (US Dollar)

Price \$21.35

Change (%) ▼ 0.91 (4.09%)

Volume 4,809,403

52 Week Low \$13.42

Market Cap \$6,655,364,585

Rolling EPS 2.21

PE Ratio 10.084

Shares Outstanding 298,983,135

Data as of 02/19/19 4:00 p.m. ET



Analyst Estimates / Ratings

Mean Recommendation: 2.1



Sell

Strong Buy

SEC Filings

Filing Date	Form	Description	Filing Group
02/15/19	4	Statement of changes in beneficial ownership of securities	3,4,5
02/15/19	4	Statement of changes in beneficial ownership of securities	3,4,5
02/15/19	4	Statement of changes in beneficial ownership of securities	3,4,5

Corporate Governance

Michael Morrissey, Ph.D.	President and Chief Executive Officer
Gisela M. Schwab, MD	President, Product Development and Medical Affairs and Chief Medical Officer
Christopher J. Senner	Executive Vice President and Chief Financial Officer
Dana Aftab Ph.D.	Executive Vice President, Business Operations
Laura Dillard	Senior Vice President, Human Resources
P.J. Haley, MBA	Senior Vice President, Commercial
Jeffrey J. Hessekiel, J.D.	Executive Vice President and General Counsel
Susan Hubbard	Executive Vice President, Public Affairs and Investor Relations
Peter Lamb, Ph.D.	Executive Vice President, Scientific Strategy and Chief Scientific Officer

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	474	4,740.46	80.0	239,118,104
Mutual Fund	508	2,863.13	44.5	133,068,633
Insider *	16	100.62	1.5	4,535,475

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
BlackRock Institutional Trust Company, N.A.	28,218,059	9.4	468,705	12/31/18
The Vanguard Group, Inc.	27,335,719	9.1	808,630	12/31/18
Fidelity Management & Research Company	21,308,335	7.1	-3,205,979	12/31/18
Meditor Capital Management Limited	15,966,038	5.3	0	12/31/18
AQR Capital Management, LLC	10,831,112	3.6	7,871,625	12/31/18
State Street Global Advisors (US)	9,241,323	3.1	-2,041,344	12/31/18
Consonance Capital Management LP	6,645,113	2.2	2,766,063	12/31/18
JP Morgan Asset Management	6,511,524	2.2	2,260,279	12/31/18

Data provided by Nasdaq. Minimum 15 minutes delayed.